• BioCryst Pharmaceuticals Inc BCRX.OQ reported quarterly breakeven results​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of eleven analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -10 cents to -4 cents per share.

• Revenue rose 56.9% to $145.53 million from a year ago; analysts expected $126.87 million.

• BioCryst Pharmaceuticals Inc's reported EPS for the quarter was breakeven results​.

• The company reported quarterly net income of $32 million.

• BioCryst Pharmaceuticals Inc shares had risen by 19.1% this quarter and gained 18.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $15.00

This summary was machine generated from LSEG data May 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)